Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This prospective study reported that 5 mg daily oral low-dose minoxidil over 24 weeks led to a high prevalence of hypertrichosis in 93% of male androgenetic alopecia patients, particularly affecting younger individuals, but generally had minimal impact on patients’ quality of life.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

Systemic therapies improve nail psoriasis but have high side effects; more research is needed.

The study explores the potential effectiveness of low-dose oral minoxidil in treating short anagen hair syndrome, suggesting it may be a viable treatment option despite the condition often resolving spontaneously with puberty.

In this study at Tohoku University Hospital, 41% of severe alopecia areata patients achieved significant hair regrowth with baricitinib treatment over 9 months, with predictors of better outcomes including shorter disease duration, female sex, initial mild disease, certain alopecia types, and prior IVMP therapy.

This study aimed to examine traditional and modern treatments for androgenetic alopecia by reviewing existing literature, highlighting the condition's varied prevalence across different populations, with higher rates in men and notably lower in women and Eastern populations.

This study investigated the production of β-cyclodextrin from ginkgo seeds, finding that a pretreatment scheme involving high-temperature gelatinization significantly improved the conversion rate to 72.63%, highlighting the industrial potential of underutilized ginkgo seed powder for sustainable applications.

This study observed that transgenic mice with overexpression of HE4 developed keratitis and severe corneal opacity, suggesting that HE4 may significantly influence keratopathy and inflammatory responses in the eye.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

In this cross-sectional study, both follicular lichen planus and discoid lupus erythematosus were identified as common causes of scarring alopecia, affecting young people with a more favorable prognosis for hair regrowth in discoid lupus erythematosus compared to follicular lichen planus.

This case study describes a 45-year-old man who developed post-finasteride syndrome with various symptoms after stopping Finasteride, highlighting the condition's rarity and poorly understood pathophysiology.

This study found that sulfotransferase enzyme levels significantly impact the effectiveness of minoxidil in treating androgenetic alopecia, suggesting that testing for this enzyme could help identify potential responders before treatment.

In this review, the researchers reported that 5α-reductase inhibitors demonstrated neuroprotective effects and reduced dyskinesias in animal models of Parkinson's disease, suggesting their potential for repurposing to manage symptoms in men with PD.

This study reports that among patients treated with dupilumab, a minority developed new-onset alopecia areata, but the majority experienced hair regrowth despite continuing the treatment.

This study observed that some patients experienced alopecia areata during dupilumab treatment for atopic dermatitis, but many regrew hair while continuing therapy.

This study found that females with chronic diffuse hair loss, including chronic telogen effluvium and female pattern hair loss, had significantly lower serum ferritin levels compared to controls, suggesting a strong association between decreased iron stores and hair loss.

This study found that topical minoxidil significantly enhanced facial hair growth in transgender individuals assigned female at birth undergoing gender affirming hormone therapy, with improvements most notable after six months of use.

This study found that thrombocytopenia is a common side effect of valproic acid, affecting up to 54% of elderly patients, but it is under-investigated despite significant therapeutic consequences.

This study reports that acute telogen effluvium, characterized by sudden hair loss occurring 2 to 3 months after a physical stressor, is not widely caused by daily life stress, with spontaneous regrowth usually happening within 3 to 6 months unless the trigger recurs.

This study found that substituting soy hulls for corn-based supplements did not significantly affect ewe growth, reproductive performance, or lamb performance in pasture-based hair sheep systems.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

In this study, isotretinoin treatment for acne vulgaris was associated with changes in plasma phosphorus, potassium, magnesium, and zinc levels, potentially affecting kidney function and contributing to side effects like fatigue and dry skin.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

In this randomized controlled trial involving breast cancer patients undergoing chemotherapy, this study investigated the efficacy of low-level light therapy for preventing hair loss, measuring outcomes like hair count and patient quality of life, but the abstract does not report specific results.

This review discusses the mechanisms, uses, and side effects of conventional synthetic DMARDs, particularly methotrexate, for rheumatoid arthritis, but reports no new clinical findings.

Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.

This article examines the ethical concerns and marketing practices of follicular unit excision hair restoration surgery, highlighting misconceptions such as "scarless surgery," without presenting new clinical findings.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

This case report presented the successful treatment of a patient with alopecia universalis using tofacitinib.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.